SCHEMBL25966972

SCHEMBL25966972

CCCn1ncc2c(C(=O)O)cccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 5/20 0.48
POLB P06746 2/20 0.47
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
THRB P10828 1/20 0.43
KMO O15229 1/20 0.42
HPGD P15428 3/20 0.42
HSD17B10 Q99714 2/20 0.42
KDM4E B2RXH2 1/20 0.42
FABP4 P15090 2/20 0.40
CNR2 P34972 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
RECQL P46063 1/20 0.39
ALDH1A1 P00352 2/20 0.39
HCAR3 P49019 1/20 0.39
NR1I2 O75469 1/20 0.39
CYP1A2 P05177 1/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 1/20 0.39
CNR1 P21554 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30622483 0.88 HPGD (0.41) KDM4CPOLBMEN1KMT2ATHRB
SCHEMBL30547754 0.87 KMO (0.43) KDM4CPOLBMEN1KMT2ATHRB
SCHEMBL30622472 0.85 POLB (0.41) KDM4CPOLBMEN1KMT2AKMO
SCHEMBL30622541 0.85 KDM4C (0.51) KDM4CKMOHPGDHSD17B10KDM4E
SCHEMBL15999085 0.85 KDM4E (0.40) KDM4CPOLBMEN1KMT2ATHRB
SCHEMBL15999099 0.85 SCN9A (0.49) KDM4CPOLBMEN1KMT2ATHRB
SCHEMBL15987446 0.85 CYP11B2 (0.48) KDM4CPOLBMEN1KMT2ATHRB
SCHEMBL25969296 0.82 KDM4C (0.44) KDM4CPOLBKMOHPGDHSD17B10
SCHEMBL15999086 0.81 KDM4C (0.41) KDM4CPOLBMEN1KMT2ATHRB
SCHEMBL15999091 0.81 KDM4E (0.39) KDM4CPOLBKMOHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250088-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250088-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 KDM4C 4078/4885POLB 394/4885MEN1 2332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.